July 1, 2019
This feature highlights changes in clinical research organizations’ personnel.
Former FDA Commissioner Scott Gottlieb has joined the board of directors at Pfizer. Gottlieb will serve on two different board-level committees, the Regulatory and Compliance Committee and the Science and Technology Committee.
Zelluna Immunotherapy has announced the appointment of Jens-Peter Marschner as chief medical officer. Marschner was previously Abbvie’s oncology medical lead for Western Europe and Canada.
Cambrex Corporation has announced three senior appointments. Dottie Donnelly-Brienza has been named senior vice president and chief human resources officer; Bruno Biscaro has been appointed president, drug products; and Joe Nettleton has been named president, drug substance. Brienza most recently served as chief human resources officer at Cantel Medical. Biscaro was previously president, North America at Famar. Nettleton previously held the position of vice president, U.S. operations with Cambrex.
Deidre Roniger has been appointed senior vice president, corporate development and Amanda Valentino as chief people officer at Ambys Medicines. Roniger was previously managing partner at DNA Ink. Valentino was most recently the senior director of talent acquisition and strategy at Genentech.
TB Alliance has named Eugene Sun to the position of senior vice president for research and development. Sun was previously the senior advisor to the HHS Biomedical Advanced Research and Development Authority.
Eelco Ockers has been appointed executive vice president, Germany at STADA. Ockers was most recently regional director DACH & Nordics at Reckitt Benckiser.
eXIthera Pharmaceuticals has named Michael Kurz as vice president of translational medicine and medical affairs at the clinical-stage biotechnology company. Kurz previously served as executive director and head of translational medicine and medical affairs at Edge Therapeutics.
José Trevejo has been named chief executive officer at SmartPharm Therapeutics. Trevejo, a co-founder of SmartPharm, was most recently vice president, clinical development at Cyclerion Therapeutics.
DBV Technologies has appointed Pharis Mohideen as chief medical officer of DBV Technologies, effective July 22. Hugh Sampson, who assumed the role of interim CMO in early 2019, will continue with the company as chief scientific officer. Mohideen most recently served as chief medical officer with Millendo Therapeutics.
Evan Loh has been promoted to chief executive officer at Paratek Pharmaceuticals. Loh has served as chief operating officer at Paratek since January 2017 and as president and chief medical officer since June 2014. Michael Bigham, who had served as the chairman and CEO since 2014, will remain with the company in the newly created role of executive chairman.
Amunix Pharmaceuticals has named Bryan Irving as chief scientific officer. Irving was previously chief scientific officer at Five Prime.
Peter Collum has been appointed chief financial officer and chief business officer at Pharnext SA. Collum was most recently a partner at MTS Health Partners.
Abeona Therapeutics Inc. has announced the appointment of Victor Paulus as senior vice president, regulatory affairs, and Jodie Gillon as vice president of patient advocacy and clinical affairs. Paulus was previously vice president and global head of regulatory affairs at clinical-stage immunotherapy company Hookipa Pharma. Gillon previously spent more than a decade with Pfizer as the global medical lead for patient engagement within the rare diseases unit and the director of medical communications within the chief medical office.
John Leaman has been named chief financial officer at Impel NeuroPharma. Leaman was formerly the chief financial officer and head of corporate development at Selecta Biosciences.
Parata Systems has announced the appointment of Rocco Volpe as chief operating officer. Volpe was previously vice president, global operations at Cognex Corporation.
Bhaskar Sambasivan has been named president, patient services and chief strategy officer at EVERSANA. Sambasivan was most recently the senior vice president and global head, life sciences at Cognizant.
Stefano Giolito has been appointed chief marketing officer at RevoluGen. Giolito was previously the marketing global vice president of Unilever.